Paul L. Nguyen, MD, of the Dana-Farber Cancer Institute, summarizes a session he moderated, which included talks on local recurrence following brachytherapy, long-term PSA stability after the procedure, and androgen deprivation and high-dose radiotherapy. (Scientific Session 41)
Anders Widmark, MD, PhD, of the Umea University Hospital Oncology, discusses the early toxicity results from the phase III Scandinavian study on extreme hypofractionation vs conventionally fractionated radiotherapy for intermediate-risk prostate cancer. (Abstract LBA-5)
Lia M. Halasz, MD, of the University of Washington Seattle Cancer Care Alliance, summarizes a session on the uneven delivery of radiotherapy in the United States and around the world. (Scientific Session 10)
Richard T. Hoppe, MD, of Stanford University, summarizes a session on improving outcomes by enhancing old and new indications in follicular lymphoma and Hodgkin lymphoma. (Scientific Session 5)
Maria Werner-Wasik, MD, of Thomas Jefferson University Hospital, summarizes a session she moderated on lung toxicity, including the impact of cardiac radiation, the risk of radiation to thoracic vertebral bodies, radiation pneumonitis, and upfront SBRT. (Scientific Session 39)
Douglas W. Arthur, MD, of Virginia Commonwealth University, discusses the 3-year efficacy report from a phase II study of repeat breast-preserving surgery and 3D conformal partial breast reirradiation for in-breast recurrence. (Abstract LBA-10)
